Lyell Immunopharma, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2019 | $39.5M | $23.4M | $16.0M | $15.7M |
| FY2020 | $-160.9M | $-212.4M | $51.5M | $33.3M |
| FY2021 | $-126.2M | $-191.8M | $65.5M | $62.2M |
| FY2022 | $-169.6M | $-193.8M | $24.3M | $81.9M |
| FY2023 | $-163.7M | $-166.4M | $2.7M | $47.1M |
| FY2024 | $-162.4M | $-162.9M | $464.0K | $33.1M |
| FY2025 | $-150.0M | $-150.8M | $780.0K | $41.8M |